Comments on "Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema".
作者信息
Yang Yang, Zhang Junyan
机构信息
Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, China.
Department of Clinical Epidemiology and Evidence-Based Medicine, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China. E-mail:
出版信息
Invest Ophthalmol Vis Sci. 2025 Aug 1;66(11):52. doi: 10.1167/iovs.66.11.52.
Abstract
摘要
相似文献
1
Comments on "Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema".关于“糖尿病性黄斑水肿患者从阿柏西普转换为法西单抗后的真实世界转归”的评论
Invest Ophthalmol Vis Sci. 2025 Aug 1;66(11):52. doi: 10.1167/iovs.66.11.52.
2
Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema.在糖尿病性黄斑水肿的约塞米蒂/莱茵试验中，法西单抗与阿柏西普的解剖学对照
Ophthalmol Retina. 2025 Jul;9(7):655-666. doi: 10.1016/j.oret.2025.01.017. Epub 2025 Feb 4.
3
Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab.从阿柏西普转换为 faricimab 治疗抵抗性新生血管年龄相关性黄斑变性的结局。
Ophthalmol Retina. 2024 Jun;8(6):537-544. doi: 10.1016/j.oret.2023.11.015. Epub 2023 Nov 29.
4
IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS.在3期约塞米蒂和莱茵试验中，法西单抗与阿柏西普对糖尿病性黄斑水肿患者2年内视网膜前膜形成的影响
Retina. 2025 Jul 14. doi: 10.1097/IAE.0000000000004572.
5
Author Response: Retina Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema.作者回复：糖尿病性黄斑水肿患者从阿柏西普转换为法西单抗后的视网膜真实世界转归
Invest Ophthalmol Vis Sci. 2025 Aug 1;66(11):51. doi: 10.1167/iovs.66.11.51.
6
Switching to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular edema: a systematic review and meta-analysis.在先前接受抗血管内皮生长因子治疗后转为使用法西单抗治疗持续性糖尿病黄斑水肿：一项系统评价和荟萃分析
Graefes Arch Clin Exp Ophthalmol. 2025 Jun 27. doi: 10.1007/s00417-025-06878-7.
7
Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion.法西单抗治疗视网膜静脉阻塞所致黄斑水肿的短期真实世界疗效
Int J Retina Vitreous. 2025 Jul 15;11(1):79. doi: 10.1186/s40942-025-00703-3.
8
Six-month comparative outcomes of aflibercept and faricimab in treatment-naïve macular edema secondary to branch retinal vein occlusion.阿柏西普和法西单抗治疗初治的视网膜分支静脉阻塞继发黄斑水肿的6个月比较结果。
Jpn J Ophthalmol. 2025 Jul 22. doi: 10.1007/s10384-025-01254-8.
9
Faricimab Outcomes in Chorioretinal Disorders: Indian Real-World Analysis (FOCUS Study).法西单抗治疗脉络膜视网膜疾病的真实世界研究结果：印度真实世界分析（FOCUS研究）
Clin Ophthalmol. 2025 Jun 12;19:1855-1862. doi: 10.2147/OPTH.S521384. eCollection 2025.
10
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.抗血管内皮生长因子治疗糖尿病性黄斑水肿：一项网状Meta分析。
Cochrane Database Syst Rev. 2017 Jun 22;6(6):CD007419. doi: 10.1002/14651858.CD007419.pub5.
本文引用的文献
1
Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema.糖尿病性黄斑水肿患者从阿柏西普转换为法西单抗后的真实世界转归
Invest Ophthalmol Vis Sci. 2024 Dec 2;65(14):46. doi: 10.1167/iovs.65.14.46.
2
When to p and when not to p.该做还是不做。
Neurogastroenterol Motil. 2023 Nov;35(11):e14672. doi: 10.1111/nmo.14672. Epub 2023 Sep 5.
3
Reversing Bonferroni.反转 Bonferroni 校正。
Psychon Bull Rev. 2021 Jun;28(3):788-794. doi: 10.3758/s13423-020-01855-z. Epub 2021 Jan 19.
4
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.《流行病学观察性研究报告强化（STROBE）声明》：观察性研究报告指南
Ann Intern Med. 2007 Oct 16;147(8):573-7. doi: 10.7326/0003-4819-147-8-200710160-00010.
5
Multiplicity in randomised trials I: endpoints and treatments.随机试验中的多样性I：终点和治疗方法。
Lancet. 2005;365(9470):1591-5. doi: 10.1016/S0140-6736(05)66461-6.
6
Cohort studies: marching towards outcomes.队列研究：迈向研究结果
Lancet. 2002 Jan 26;359(9303):341-5. doi: 10.1016/S0140-6736(02)07500-1.
Zotero 插件